Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
Authors
Jonathan Silverberg,
Andreas WollenbergLinda Gold,
J.Q. Rosso,
Gil Yosipovitch,
Peter Lio,
J.M. Carrascosa,
Gaia Gallo,
Yuxin Ding,
Zhenhui Xu,
Marta Casillas,
Evangeline Pierce,
Helena Agell,
Sonja Ständer +12 authors
,
M. Casillas Tip Tip